Sale!

Research Paper on A Particular Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma Is Bone Marrow Infiltration

Original price was: ₹21,240.00.Current price is: ₹10,620.00. inc. GST

Research Paper on A Particular Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma Is Bone Marrow Infiltration

1 in stock

Description

Title: A Particular Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma Is Bone Marrow Infiltration

Abstract: Background. Patients with CD20-positive B-cell non-Hodgkin lymphoma may be at risk for infusion-related reactions (IRRs) due to lymphoma cells infiltrating their bone marrow (B-NHL). The impact of B-NHL cell infiltration in the bone marrow on the incidence rate of grade 2 or higher IRRs with the administration of rituximab has been retrospectively studied in this paper, despite the lack of sufficient data. Methods. In this study, participants with B-NHL that was CD20-positive and receiving rituximab induction therapy for the first time were included. May-Giemsa staining of bone marrow films and flow cytometry analysis of bone marrow aspiration samples were carried out to assess the B-NHL cell infiltration of the bone marrow. The Common Terminology Criteria for Adverse Events version 4.0’s IRR criteria were used to calculate the IRR grade. Results. 127 patients in total were qualified for this study. In 43 (34%) of the patients, IRRs of grade 2 or higher were noted. Use of glucocorticoids prior to rituximab infusion was found to be a significant risk-reducing factor for grade 2 or higher IRRs in univariate analysis. Regardless of glucocorticoid premedication, advanced disease stages (Ann Arbor: stages III and IV) or bone marrow infiltration of B-NHL cells revealed the risk factors. In patients who had never taken glucocorticoids before, bone marrow infiltration was discovered to be a separate risk factor using multivariate analysis. Conclusion. A risk factor for grade 2 or higher IRRs at the first round of rituximab induction therapy without glucocorticoid premedication is the presence of B-NHL cells infiltrating the bone marrow.

Paper Quality: SCOPUS / Web of Science Level Research Paper

Subject: Medicine

Sub Category: Hematology

Writer Experience: 20+ Years

Plagiarism Report: Turnitin Plagiarism Report will be less than 10%

Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.

What will I get after the purchase?

A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.

In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.